Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname.

Barro M, Some J, Foulongne V, Diasso Y, Zouré E, Hien H, François R, Michel S, Drabo A, Tamboura H, Ouiminga A, Diagbouga S, Hien A, Yaméogo S, Van De Perre P, Nacro B, Msellati P.

J Acquir Immune Defic Syndr. 2011 Jul 1;57 Suppl 1:S44-9. doi: 10.1097/QAI.0b013e31821fd64f.

PMID:
21857286
2.

24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.

Hien H, Meda N, Diagbouga S, Zoure E, Yaméogo S, Tamboura H, Somé J, Ouiminga A, Rouet F, Drabo A, Hien A, Nicolas J, Chappuy H, Van de Perre P, Msellati P, Nacro B.

Afr Health Sci. 2013 Jun;13(2):287-94. doi: 10.4314/ahs.v13i2.13.

3.

Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.

Skowron G, Kuritzkes DR, Thompson MA, Squires KE, Goodwin SD, Dusak BA, Tolson JM, Stevens M, Yuen GJ, Rooney JF; Intercompany Collaboration for AIDS Drug Development Protocol 604 Team..

J Infect Dis. 2002 Oct 1;186(7):1028-33. Epub 2002 Sep 13. Erratum in: J Infect Dis 2002 Dec 15;186(12):1872.

PMID:
12232846
4.

Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.

de Mendoza C, Soriano V, Pérez-Olmeda M, Rodríguez-Rosado R, González-Lahoz J.

J Hum Virol. 2000 Nov-Dec;3(6):335-40.

PMID:
11100914
5.

Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.

Sánchez-Conde M, Palacios R, Sanz J, Rodríguez-Novoa S, Rivas P, Santos J, Sola J, Asensi V, de Mendoza C, Estrada V, Barreiro P, González-Lahoz J, Jiménez-Nacher I, Soriano V.

AIDS Res Hum Retroviruses. 2007 Oct;23(10):1237-41.

PMID:
17961110
6.

Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: the VESD study.

Santos J, Palacios R, López M, Gálvez MC, Lozano F, de la Torre J, Ríos MJ, López-Cortés LF, Rivero A, Torres-Tortosa M; Grupo Andaluz para el Estudio de las Enfermedades Infecciosas..

HIV Clin Trials. 2005 Nov-Dec;6(6):320-8.

PMID:
16566083
8.

Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.

McKinney RE Jr, Rodman J, Hu C, Britto P, Hughes M, Smith ME, Serchuck LK, Kraimer J, Ortiz AA, Flynn P, Yogev R, Spector S, Draper L, Tran P, Scites M, Dickover R, Weinberg A, Cunningham C, Abrams E, Blum MR, Chittick GE, Reynolds L, Rathore M; Pediatric AIDS Clinical Trials Group Protocol P1021 Study Team..

Pediatrics. 2007 Aug;120(2):e416-23. Epub 2007 Jul 23.

PMID:
17646352
9.

Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.

Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.

Antivir Ther. 2005;10(5):605-14.

PMID:
16152754
10.

A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.

Mole L, Schmidgall D, Holodniy M.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):260-5.

PMID:
11464145
11.
12.

Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.

Santos J, Palacios R, Lozano F, López M, Gálvez MC, de la Torres J, López-Cortés LF, Ríos MJ, Rivero A; Grupo Andaluz Para el Estudio de las Enfermedades Infecciosas (GAEI)..

AIDS Res Hum Retroviruses. 2008 Jan;24(1):24-6. doi: 10.1089/aid.2007.0142.

PMID:
18275344
13.

Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz.

Maggiolo F, Migliorino M, Maserati R, Pan A, Rizzi M, Provettoni G, Rizzi L, Suter F; Once Study Group..

Antivir Ther. 2001 Dec;6(4):249-53.

PMID:
11878406
14.

Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.

Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E; GESIDA 3903 Team..

Clin Infect Dis. 2008 Oct 15;47(8):1083-92. doi: 10.1086/592114. Erratum in: Clin Infect Dis. 2008 Dec 15;47(12):1611.

PMID:
18781872
15.

Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients.

Raffi F, Reliquet V, Auger S, Besnier JM, Chennebault JM, Billaud E, Michelet C, Perre P, Lafeuillade A, May T, Billaudel S.

AIDS. 1998 Oct 22;12(15):1999-2005.

PMID:
9814868
16.

Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children.

Funk MB, Linde R, Wintergerst U, Notheis G, Hoffmann F, Schuster T, Kornhuber B, Ahrens P, Kreuz W.

AIDS. 1999 Sep 10;13(13):1653-8.

PMID:
10509566
17.

The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.

Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.

HIV Med. 2005 Mar;6(2):122-8.

18.

Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.

Crespo M, Ribera E, Suárez-Lozano I, Domingo P, Pedrol E, López-Aldeguer J, Muñoz A, Viladés C, Sánchez T, Viciana P, Teira R, García-Alcalde ML, Vergara A, Lozano F, Galindo MJ, Cosin J, Roca B, Terrón A, Geijo P, Vidal F, Garrido M; VACH Cohort Study Group..

J Antimicrob Chemother. 2009 Jan;63(1):189-96. doi: 10.1093/jac/dkn450. Epub 2008 Nov 6.

PMID:
18988678
19.

Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).

Gallien S, Journot V, Rozenbaum W, Yéni P, Morlat P, Poizot-Martin I, Reynes J, Reliquet V, Leclercq P, Simon F, Chêne G, Molina JM; ALIZE (ANRS 099) Study Group..

J Antimicrob Chemother. 2011 Jan;66(1):184-91. doi: 10.1093/jac/dkq395. Epub 2010 Oct 28.

PMID:
21036772
20.

Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.

Scherpbier HJ, Bekker V, Pajkrt D, Jurriaans S, Lange JM, Kuijpers TW.

Pediatrics. 2007 Mar;119(3):e705-15. Epub 2007 Feb 16.

PMID:
17308244

Supplemental Content

Support Center